Sign In
Get Clay Free →

Suggestions

    Michael Gilman

    Biotechnology Executive

    Michael Gilman is a prominent figure in the biotechnology industry with a wealth of experience in executive leadership roles.

    Currently serving as the Chief Executive Officer at Arrakis Therapeutics, Michael has demonstrated his strategic vision and business acumen in steering the company towards success.

    Prior to his role at Arrakis Therapeutics, he held the position of Chief Executive Officer at Obsidian Therapeutics, showcasing his versatility and adaptability in managing different organizations.

    With a strong entrepreneurial spirit, Michael founded and led multiple companies, including Padlock Therapeutics and Stromedix, Inc., where he played a pivotal role in driving innovation and growth.

    His tenure at Biogen Idec, where he served as Senior Vice President of the Early Stage Pipeline and later as Executive Vice President of Research, further solidified his reputation as a leader in the field of biotechnology.

    Michael's extensive experience also includes holding the role of Executive Vice President and Chief Scientific Officer at ARIAD Pharmaceuticals, where he made significant contributions to the company's research and development efforts.

    His scientific expertise was honed during his time as a Senior Staff Scientist at Cold Spring Harbor Laboratory and as a Postdoctoral Fellow at Whitehead Institute, reflecting his deep understanding of molecular biology and drug discovery.

    Throughout his career, Michael Gilman has consistently demonstrated his commitment to advancing the biotechnology sector through innovative strategies and leadership initiatives.

    Related Questions

    What are Michael Gilman's key achievements at Arrakis Therapeutics?
    How did Michael Gilman's role at Biogen Idec prepare him for his current position?
    What is the significance of the TRYST and PEARL-seq platforms at Arrakis Therapeutics?
    How did Michael Gilman transition from academia to the biotech industry?
    What are the main diseases targeted by Arrakis Therapeutics' RNA-targeted small molecules?
    Michael Gilman
    Michael Gilman, photo 1
    Michael Gilman, photo 2
    Get intro to Michael
    Add to my network

    Experience

    Chief Executive Officer at Arrakis Therapeutics
    Chief Executive Officer at Obsidian Therapeutics, Founder and CEO at Padlock Therapeutics, Senior VP at Biogen Idec, Founder and CEO at Stromedix, Inc., Executive VP at Biogen, Executive VP and Chief Scientific Officer at ARIAD Pharmaceuticals, Senior Staff Scientist at Cold Spring Harbor Laboratory, Postdoctoral Fellow at Whitehead Institute

    Location

    Waban, Massachusetts, United States